nContact, Inc. Announces First Patient Treated In The CONVERGE IDE Clinical Trial - The First Head-To-Head Superiority Study Comparing The Multidisciplinary Convergent Procedure To Endocardial Catheter Ablation In Persistent Atrial Fibrillation Patients
Published: Jan 09, 2014
MORRISVILLE, N.C., Jan. 8, 2014 (GLOBE NEWSWIRE) -- nContact, Inc. today announced the first patient treated in the CONVERGE IDE Clinical Trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, estimated to affect 5.9 million people in the U.S., with a majority of patients falling into the difficult-to-treat persistent AF population. The CONVERGE Study is designed to investigate the treatment of persistent AF patients with the multidisciplinary Convergent Procedure, an epicardial-endocardial approach that utilizes the collaborative expertise and techniques of an electrophysiologist and cardiothoracic surgeon.
Help employers find you! Check out all the jobs and post your resume.